Anti Diabetes medicine by CSIR

The diabetic population in the country is close to hitting the alarming mark of 69.9 million by 2025, which denotes that the country is expected to witness an increase of 266%.

The diabetic population in the country is close to hitting the alarming mark of 69.9 million by 2025, which denotes that the country is expected to witness an increase of 266%.

Council of Scientific and Industrial Research (CSIR), through its constituent laboratories namely CSIR-Central Institute of Medicinal & Aromatic Plants (CSIR-CIMAP), Lucknow; and CSIR-National Botanical Research Institute (CSIR-NBRI), Lucknow developed scientifically validated herbal product NBRMAP-DB as anti-diabetic formulation and the knowhow for the product was licensed to M/s AIMIL Pharma Ltd., Delhi who are manufacturing and marketing it as BGR-34, across the country.

 M/s AIMIL Pharmaceuticals, the licensee carried out the clinical study of BGR-34 and the trial was registered in the clinical trial registry of India (Registration number: CTRI/2016/11/007476). Further, the formulation has shown therapeutic efficacy for treating newly diagnosed type 2 diabetes, as found in independent clinical trials conducted at Banaras Hindu University (BHU), Varanasi.

 

The Central of Research in Ayurveda Sciences (CCRAS), an autonomous body under Ministry of AYUSH has been engaged in extending research-oriented Ayurveda based on integrative health care services for the management of Madhumeha which is Diabetes Mellitus. The following are the core activities

CCRAS  in collaboration with Directorate General of Health Services, Ministry of Health & Family Welfare has implemented and executed a programme viz. Integration of AYUSH (Ayurveda) component with NPCDCS(National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular diseases & Stroke ) programme in the identified districts of 3 states viz. Bhilwara (Rajasthan), Surendranagar (Gujarat) and Gaya (Bihar) to cater health care services and to reduce the burden of NCDs including Diabetes by combining the strength of Ayurveda and Yoga. The programme was launched during 2016 and continuing in 3 districts viz. Bhilwara (Rajasthan), Surendranagar (Gujarat) and Gaya (Bihar). The aforesaid programme is now successfully functional in 52 centres (49 CHCs and 3 District Hospitals) of the all 3 identified districts, through AYUSH- NPCDCS Clinic/Lifestyle modification Clinics, established for prevention and management of selected NCDs by Ayurvedic intervention, Lifestyle modifications and Yoga Advice.

CCRAS had developed the AYUSH82 formulation for diabetes through the scientific process of drug development and commercialized through National Research Development Corporation (NRDC) for wider public utility.

 Generation of evidence on efficacy & safety of classical Ayurveda formulation on Diabetes Mellitus. CCRAS has done efficacy and safety on formulations viz. Nishamalki churna, Saptvinsti Gugullu,  Yasad bhasm, Guduchi churna, Chandraprabha Vati, Haridra churna and Gokshuradi Gugullu.

 

CCRAS has published the documents viz. Protocol on Prevention and Management for Diabetes Mellitus and compendium on research articles on Diabetes Mellitus which are made available in the public domain for benefit of practitioner’s, physician and researchers

 This information was given by the Minister of State (Independent Charge) for AYUSH, Shri Shripad Yesso Naik in written reply to a question in Lok Sabha today.

 

Tags : #medicine #diabetes #medicircle

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Gynoveda, India's First Ayurveda Fertility Company, Expands Reach with New Clinic in Pune, Set to Open 100 Clinics Across India by 2027May 03, 2024
Aptus Value Housing Finance India Limited, a leading Housing Finance Company has declared its financial results for the year ended March 31, 2024. FY 24 ResultsMay 03, 2024
TIPS FOR PREGNANCY CARE DURING SUMMERMay 03, 2024
The deadly intersection: TB and tobacco smoking co-epidemics in Indonesia Dr TARA SINGH BAM – CNSMay 03, 2024
Mintoak Expands Global Footprint with Strategic Leadership AppointmentsMay 03, 2024
The Future of Healthcare: 10 ways Telehealth is Improving Patient Outcomes and Reducing CostsMay 03, 2024
Understanding the Effects of a Keto Diet on Your Body: A One-Month JourneyMay 03, 2024
High Blood Pressure in Youth: A Precursor to Severe Heart ConditionsMay 03, 2024
High Blood Pressure in Youth: A Precursor to Severe Heart ConditionsMay 03, 2024
Microplastics in Human Brains: Understanding the Emerging Health ConcernMay 03, 2024
Federal Bank Wraps Up FY 24 With 24% Rise in Profit, highest NII, Maintains Robust Asset QualityMay 02, 2024
Two Aveksha Day Care Centers for Construction Workers’ Children opened on the occasion of Labour Day May 02, 2024
AbbVie India and Sightsavers India Collaborate to Raise Awareness on GlaucomaMay 02, 2024
Whither social justice and decent work for women?May 02, 2024
Hyderabad's senior anesthesiologist at the L V Prasad Eye Institute, Dr Raja Narsing Rao elected as President of the World Congress of Ophthalmic AnaesthesiaMay 02, 2024
Navigating Legal Waters: Covishield's Side Effects Prompt Legal Battle from Parents May 02, 2024
Mumps Resurgence in India: Understanding the Recent Outbreak and Prevention StrategiesMay 02, 2024
Genomic Insights Unveiled: Illumina and Garvan Institute Collaborate to Map Disease FingerprintsMay 02, 2024
2 Months Post-Surgery, Patient Returns To Normal Life After Wide-Glossectomy With Microvascular ReconstructionApril 30, 2024
Wolfpack Labs - Aakash Anand Launches New Venture Studio Fostering Growth and Collaboration Among Early-Stage Entrepreneurs; Aims to become the biggest seeder of GTM-ready startups for leading VCsApril 30, 2024